ImmunoBiota Therapeutics
PrivateLast Round
Seed
Aug 29, 2026
Total Funding Raised
$67,000
Momentum
Top 1%
of companies Caplight tracks
Company Overview
ImmunoBiota Therapeutics operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Grant round in August 2026.
ImmunoBiota Therapeutics is a biotechnology company that develops oral, non-immunosuppressive therapies for Type 1 diabetes by targeting dysfunctional microbiome metabolites.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoBiota Therapeutics Comparables
Compare ImmunoBiota Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Advanced Microbiome Interventions | 86% | |
| Precigen | 79% | |
| Imcyse | 79% |
For institutional investors. Book with your work email.
ImmunoBiota Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Aug 29, 2026 | ||||
| Grant | Aug 19, 2026 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 29, 2026
$5M round completed.
- Aug 19, 2026
$67K grant received from Diabetes Australia.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 4, 2026
In Sep '26, ImmunoBiota receives a $100K non-dilutive grant from Diabetes Australia's Grand Innovation Challenge for Excellence in Innovation in Australia, adding to its funding base as it works toward the seed close.
For institutional investors. Book with your work email.
ImmunoBiota Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmunoBiota Therapeutics's valuation, stock price, and market status.
Is ImmunoBiota Therapeutics a public or private company?
ImmunoBiota Therapeutics is a private company.
What is the current stock price of ImmunoBiota Therapeutics?
ImmunoBiota Therapeutics is a private company, so its shares have no public market price. Caplight tracks ImmunoBiota Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunoBiota Therapeutics worth (valuation)?
Valuation information for ImmunoBiota Therapeutics is not publicly available.
Can I buy ImmunoBiota Therapeutics stock?
ImmunoBiota Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunoBiota Therapeutics's last funding round?
ImmunoBiota Therapeutics's most recent funding round was Seed on August 29, 2026.
Who are the main investors in ImmunoBiota Therapeutics?
Investor information for ImmunoBiota Therapeutics is not publicly disclosed.
Will ImmunoBiota Therapeutics IPO soon?
No public IPO plans have been announced for ImmunoBiota Therapeutics.
How can I track ImmunoBiota Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ImmunoBiota Therapeutics's shares on secondary markets.